ATE241362T1 - Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält - Google Patents

Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält

Info

Publication number
ATE241362T1
ATE241362T1 AT94927583T AT94927583T ATE241362T1 AT E241362 T1 ATE241362 T1 AT E241362T1 AT 94927583 T AT94927583 T AT 94927583T AT 94927583 T AT94927583 T AT 94927583T AT E241362 T1 ATE241362 T1 AT E241362T1
Authority
AT
Austria
Prior art keywords
estrogen
progestogen
pct
substitution therapy
composition
Prior art date
Application number
AT94927583T
Other languages
English (en)
Inventor
Philippe Robert Marie Koninckx
Original Assignee
Saturnus Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saturnus Ag filed Critical Saturnus Ag
Application granted granted Critical
Publication of ATE241362T1 publication Critical patent/ATE241362T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94927583T 1993-09-09 1994-09-08 Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält ATE241362T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9301562A NL9301562A (nl) 1993-09-09 1993-09-09 Preparaat voor substitutietherapie.
PCT/EP1994/002997 WO1995007081A1 (en) 1993-09-09 1994-09-08 Preparation for substitution therapy, containing at least one progestogen and at least one extrogen

Publications (1)

Publication Number Publication Date
ATE241362T1 true ATE241362T1 (de) 2003-06-15

Family

ID=19862861

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927583T ATE241362T1 (de) 1993-09-09 1994-09-08 Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält

Country Status (12)

Country Link
US (1) US5827843A (de)
EP (1) EP0717626B1 (de)
JP (1) JPH09502194A (de)
KR (1) KR960704553A (de)
CN (1) CN1076969C (de)
AT (1) ATE241362T1 (de)
AU (1) AU708881B2 (de)
DE (1) DE69432752T2 (de)
FI (1) FI961098L (de)
HU (1) HU224818B1 (de)
NL (1) NL9301562A (de)
WO (1) WO1995007081A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9702162A (es) * 1994-09-22 1997-06-28 Akzo Nobel Nv Procedimiento para hacer unidades de dosis mediante granulacion en humedo.
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
DE19549264A1 (de) * 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
US6506390B2 (en) 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
WO1998004246A2 (en) * 1996-07-26 1998-02-05 American Home Prod Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
CN1119999C (zh) * 1996-07-26 2003-09-03 惠氏公司 口服避孕药
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
KR100913910B1 (ko) * 2000-01-18 2009-08-26 바이엘 쉐링 파마 악티엔게젤샤프트 호르몬 보충 요법용 드로스피렌온
HRP20020666B1 (hr) * 2000-01-18 2011-07-31 Bayer Schering Pharma Aktiengesellschaft Drospirenon za hormonsku nadomjesnu terapiju
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
MXPA03008367A (es) * 2001-03-16 2004-11-12 Wyeth Corp Terapia de reemplazamiento de hormonas.
EP1857110A3 (de) * 2001-03-16 2008-08-06 Wyeth Hormonersatztherapie
EP1390038A2 (de) 2001-05-16 2004-02-25 Endeavor Pharmaceuticals Behandlung von hormonellen mangelzuständen mit progestin
PT1390040E (pt) * 2001-05-18 2007-04-30 Pantarhei Bioscience Bv Composição farmacêutica para ser utilizado na terapia hormonal de substituição.
EP1260225A1 (de) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Pharmazeutische Zusammensetzung für die Hormonersatztherapie
EP1390042B1 (de) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
ES2337129T3 (es) * 2001-05-23 2010-04-21 Pantarhei Bioscience B.V. Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
JP2004521951A (ja) * 2001-07-13 2004-07-22 シエーリング アクチエンゲゼルシャフト Ｈｒｔのためのドロスピレノン及びエストロゲンスルファメートの組み合わせ
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US8026228B2 (en) * 2001-11-15 2011-09-27 Pantarhei Bioscience B.V. Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
CN100581550C (zh) * 2001-12-05 2010-01-20 杜拉美德药物有限公司 预防怀孕和减少经期前症状的口服避孕药
TW200306846A (en) * 2002-04-03 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200306196A (en) * 2002-04-03 2003-11-16 Wyeth Corp Hormone replacement therapy
TW200306851A (en) * 2002-04-29 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
PT1511496E (pt) * 2002-06-11 2007-01-31 Pantarhei Bioscience Bv Método para tratamento ou prevenção de doenças mediadas pelo sistema imunitário e formulação farmacológica para utilização nas mesmas
CN100352445C (zh) * 2002-06-11 2007-12-05 潘塔希生物科学股份有限公司 一种皮肤护理组合物及其用途
SI1526856T1 (sl) * 2002-07-12 2008-04-30 Pantarhei Bioscience Bv Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka
SI1556058T1 (sl) * 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
CN101001631B (zh) * 2003-07-16 2014-08-06 特卫华妇女健康有限公司 利用连续给予雌激素的避孕方案的激素治疗方法
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
ATE473746T1 (de) * 2007-01-08 2010-07-15 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
ITMI20122027A1 (it) * 2012-11-28 2014-05-29 Altergon Sa Soluzioni acquose orali di ormoni steroidei e hp¿cd con biodisponibilità ottimizzata

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
DE3888269T2 (de) * 1987-09-24 1994-07-07 Jencap Research Ltd Hormon-Zusammensetzung und -Anwendung.
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product

Also Published As

Publication number Publication date
CN1076969C (zh) 2002-01-02
WO1995007081A1 (en) 1995-03-16
HU9600592D0 (en) 1996-05-28
FI961098A7 (fi) 1996-04-03
HUT74452A (en) 1996-12-30
EP0717626A1 (de) 1996-06-26
CN1133011A (zh) 1996-10-09
DE69432752T2 (de) 2004-04-08
KR960704553A (ko) 1996-10-09
NL9301562A (nl) 1995-04-03
US5827843A (en) 1998-10-27
FI961098L (fi) 1996-04-03
AU7695294A (en) 1995-03-27
HU224818B1 (en) 2006-02-28
EP0717626B1 (de) 2003-05-28
DE69432752D1 (de) 2003-07-03
JPH09502194A (ja) 1997-03-04
AU708881B2 (en) 1999-08-12
FI961098A0 (fi) 1996-03-08

Similar Documents

Publication Publication Date Title
ATE241362T1 (de) Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält
IL111077A (en) Pyridine derivatives processes for the preparation thereof and pharmaceutical compositions containing them
TW285667B (de)
ZW8594A1 (en) Substituted azadioxacycbalkenes
IL151371A (en) Modified porcine factor viii and pharmaceutical compositions containing the same
GEP20012530B (en) Neuroactive Steroids of the Androstane and Pregnane Series
MX9802130A (es) Agonistas adrenergicos beta3 selectivos.
GB2364304A (en) Novel tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
DK0733046T3 (da) Benzoylguanidiner, deres fremstilling og anvendelse i medikamenter
CA2024188A1 (en) Method of treating premature ejaculation using sertraline
ATE171873T1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
IL112059A0 (en) A transdermal therapeutic composition containing a deuterated active substance
DK0593520T3 (da) Forbindelser med indhold af steroider og deres anvendelse til behandling af glaucom
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
AU695894B2 (en) Hormonal means for acne therapy and employment thereof
PT1007085E (pt) Utilizacao da hormona de crescimento em composicoes para o tratamento da resistencia a insulina no coracao
DE69109293D1 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
CA2171460A1 (en) Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
UA30722A (uk) Спосіб профілактики гнійно-септичних ускладнень у породіль
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору
MD218C2 (ro) Stimulant pentru creşterea părului

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties